At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
MK0249 +1 moredrug
Likely dose
MK0249 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia
In Brief
A Phase 2 clinical trial evaluating MK0249 and Comparator: Placebo (unspecified) for Paranoid Schizophrenia. Completed, enrolled 55 participants.
Detailed Summary
The purpose of this study is to determine the safety and effectiveness of an investigational drug MK0249 for the treatment of the cognitive impairment in patients with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParanoid Schizophrenia
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartDec 2007
Primary CompletionOct 2008
TodayJul 2026
First PostedJul 25, 2007
Enrollment StartDec 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.9 years ago
Interventions
MK0249drug
MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
Comparator: Placebo (unspecified)drug
MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.